We have also investigated the participation of signalling pathways, such as NLRP3, MAPK, PKC, and NF-κB, as well as the existing diagnostic tools and therapeutic treatments for the management of DCM. The gene discussed is NFKB1; the disease is familial dilated cardiomyopathy.